Journal of Hematalogy and Oncology Research
ISSN: 2372-6601
Current Issue
Volume No: 3 Issue No: 4
share this page

Research Article | Open Access
  • Available online freely | Peer Reviewed
  • Study of Hypercoagulability in Patients with Acute Leukaemia in the Hematology Department of Teaching Hospital of Yopougon (Abidjan)

    Mahawa Sangaré-Bamba 1 2       Valère Tchako 1     Hermance Kassi-Kablan 1 2     Rebecca N’Guessan-Blao 2     N’Dogomo Meité 3     Mireille Yayo-Ayé 1 2     Duni Sawadogo 1 2    

    1Hematology Unit, Central Laboratory, Teaching Hospital of Yopougon, Côte d’Ivoire

    2Hematology-Immunology and General Biology Laboratory Department of Pharmaceutical and Biological Sciences.

    3Clinical Hematology Department, Teaching Hospital of Yopougon.



    Acute leukaemia are the clonal and malignant proliferation of immature hematopoietic cells (blast), blocked in their differentiation process. There is an interaction between cancer cells and the clotting process. This could be the expression of Tissue Factor (TF) on the surface of tumor cells; or a lesion of the vascular endothelium and platelet activation. The result is an activation of clotting that can lead to disseminated Intravascular Coagulation (DIC). The objective of this study was to assess the risk of DIC occurring in patients with acute leukaemia.


    This was a cross-sectional study for analytical purposes that took place on 40 frozen samples from the biobank of the haematology laboratory of Teaching Hospital Yopougon for which the diagnosis of acute leukaemia had been taken from myelogram. The myelogram results were accompanied by hemogram data. PTTa, QT, fibrinogen and D-Dimers were performed on these samples. The risk assessment of DIC occurred was determined on the recommendations of the International Society of Thrombosis and Hemostasis (ISTH).


    We noted a female predominance with a Sex Ratio (M / F) of 0.90. The average age of the patients was 38 years (± 23 years) with extremes ranging from 2 to 84 years. ALL represented 20 % of cases against 80 % for AMLs. Hemogram parameters were characterized by severe anaemia (Tx Hb < 6 g / dL) in 52.5 % of cases; hyperleukocytosis > 100.103 / mm3 in 35 % of cases; thrombocytopenia < 25.103 / mm3 in 40 % of case; and significant blood and spinal cord blastosis (> 80 %). The lengthening of the PTTa was observed in 50 % of cases, compared to 40% for the QT. Similarly, hyperfibrinemia was present in 65% of cases. D-Dimers were high in almost all subject (95 % of cases). According to the ISTH criteria, 17.5 % of subjects were at risk of developing a DIC.


    The risk of occurrence of DIC is indeed present during acute leukaemia. The parameters of haemostasis are thus found to be crucial data in the follow-up assessment during the diagnosis of acute leukaemia.

    Received 24 Feb 2020; Accepted 19 Mar 2020; Published 25 Mar 2020;

    Academic Editor:Rada M. Grubovic, Head of Department for Stem Cell Collection President of Macedonian Society for Transfusion Medicine

    Checked for plagiarism: Yes

    Review by:Single-blind

    Copyright©  2020 Mahawa Sangaré-Bamba, et al.

    Creative Commons License    This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

    Competing interests

    The authors have declared that no competing interests exist.


    Mahawa Sangaré-Bamba, Valère Tchako, Hermance Kassi-Kablan, Rebecca N’Guessan-Blao, N’Dogomo Meité et al. (2020) Study of Hypercoagulability in Patients with Acute Leukaemia in the Hematology Department of Teaching Hospital of Yopougon (Abidjan). Journal of Hematalogy and Oncology Research - 3(4):1-6.
    Download as RIS, BibTeX, Text (Include abstract )


    Acute leukeamia (AL) is the clonal and malignant proliferation strains of immature hematopoietic cells, which are blocked in their differentiation process, which invade the bone marrow then the peripheral blood and finally other organs. They are characterized by at least 20 % infiltration of blast 1. World Health Organization (WHO) reports in 2018 estimate 5.2 million new cases of leukaemia worldwide; with 3.5 million deaths 2.

    During AL, hyperleukocytosis (> 50.103 / mm3) represents an emergency situation and the latter may be associated with leukostasis syndrome 3. In addition, blasts express procoagulant factors, such as tissue factor (TF), procoagulant cancer and inflammatory cytokines (interleukin 1 IL), and induce an increased generation of thrombin, leading to hypercoagulability state 4. Indeed, the adhesion of blasts at the level of endothelial cells lead to the loss of the antithrombotic properties of cells, which moreover become procoagulant 5. This activation of coagulation can cause disseminated intravascular coagulation (DIC) 6.

    DIC is a systemic pathophysiologic process and not a single disease entity, resulting from an overwhelming activation of coagulation that consumes platelets and coagulation factors and causes microvascular fibrin and thrombin, which can result in multiorgan dysfunction syndrome 7. During normal haemostasis, the clot formation at the site of vessel injury is followed clot resolution orchestrated by the fibrinolytic mechanism. This process is regulated by multiple checkpoints which prevent non-site specific activation of coagulation or clot production in the absence of endothelial damage. In DIC, these processes are dysregulated leading to massive thrombin generation which is disseminated to sites away from endothelial injury leading to organ damage 8.

    Many studies have already established the relationship between DIC and acute promyelocyte leukaemia 9-12. But what could be the risk of DIC occurring during other types of acute leukaemia? We have therefore set ourselves the general goal of studying hypercoagulability in acute leukaemia in Abidjan.

    Material and Methods

    This was a descriptive cross-sectional study with an analytical focus; which took place from September to October 2019 in the Hematology Unit of the Central Laboratory of the Teaching Hospital of Yopougon and the National Institute of Public Health; due to the accessibility of technical equipment. The study population was represented by frozen samples from the biobank of the haematology Unit of the Central Laboratory of Yopougon. Samples for which the diagnosis of acute leukaemia was made at myelogram were selected for the study. For each of these samples, the myelogram results were accompanied by the hemogram data. A total of forty samples were selected for the study. The analyses were carried out on the Sysmex CA 600 series coagulation automaton.

    The parameters studied were the partial thromboplastin time with activator (normal values: Patient / control ratio < 1.2), the Quick time (normal values: 9.1 -12.3 seconds), fibrinogen (normal values: 2 - 4 g / L) and D-Dimers (normal values ​​< 500 ng / mL). The risk of DIC occurring has been determined according to the recommendations of the International Society of Thrombosis and Haemostasis (Table 1)13.

    Table 1. Diagnostic Criteria for Disseminated Intravascular Coagulation (according to ISTH)
    Parameters Values Score
    Quick Time ≥ 3 sec 1
    ≥ 6 sec 2
    Fibrinogen ≤ 1 g/L 1
    D-Dimers >500 ng/mL 2
    Platelets ≤ 100.10³/mm³ 1
    ≤ 50 .10³/mm³ 2

    If Score ≥ 5: Risk of disseminated Intravascular Coagulation If Score <5: No risk of disseminated Intravascular Coagulation

    Statistical analyzes were performed with XLSTAT 2014 and EPI INFO version 7.2 software for Windows®. The test results of the parameters studied were reported as an average (± standard deviation). The comparison of quantitative variables was carried out with the exact Fischer-Snedecor test. The comparison of the means was carried out using Student's t tests.


    The Sex Ratio M / F was 0.9; while the most represented age group was 20 to 40 years old with 30% of cases. Clinically, tumor syndrome was present in 45% of cases. Table 2 shows the parameters of the hemogram.

    Table 2. Hemogram and Myelogram Data
      Average SD Min Max
    hemoglobin level (g/dL) 7 2.7 3.4 14.4
    WBC (103/mm3) 103.7 151.1 0.9 634
    Platelets (103/mm3) 73.2 114.2 5.8 690
    Peripheral Balsts (%) 64.5 20.6 22.0 92
    Spinal Blasts (%) 57 22.9 23.0 97

    We reported hyperleukocytosis greater than 100.103/mm3 in 35% of cases, while 87.5 % of subjects had thrombopenia. From a cytologic point of view, we observed 80 % of AMLs versus 20 % of ALLs. Within the myeloid lineage, AML 1 came first with 37.5 %, while ALL 2 came first in the lymphoid lineage with 15 % of cases.

    At haemostasis, a prolongation of the PTTa was observed in 50 % of cases and a prolongation of the QT in 40 % of the cases. D-dimers were high in 95 % of subjects, while only 65 % of subjects had fibrinogen elevation. Table 3 presents haemostasis data.

    Table 3. Haemostasis data.
      Average SD Min Max
    PTTa (seconds) 32.6 16.0 19.8 103
    QT (seconds) 13.07 2.26 10 21.7
    FIBRINOGEN (g/L) 5.3 1.8 2.1 8.8
    D-DIMERS (ng/mL) 3769 2947 404 8945

    According to the ISTH criteria, only 17.5 % of subjects were at risk of developing a DIC. Table 4 shows the distribution of DIC according to the leukemic type.

    Table 4. Distribution of DIC by leukaemia type.
    Type of leukaemia DIC workforce / Total workforce
    ALL 1 0/2
    ALL 2 1/6
    Subtotal AML 1/8
    AML 0 ¼
    AML 1 2/15
    AML 2 2/11
    AML 3 1/1
    AML 5 0/1
    Subtotal AML 6/32
    TOTAL 7/40

    (Table 5) presents the results of the comparison between the parameters of the study population and the risk of DIC.

    Table 5. Parameters of the study population according to the risk of DIC
    Parameters DIC risk present DIC risk absent p Value (α = 5 %)
    Age (average) 40 38 0,8
    Sex: M/F  (workforce) 2/5 17/16 0,4
    hemoglobin level g/dL (average) 7,3 7 0,8
    WBC 103/mm3 (average) 180,6 87,4 0,3
    Spinal Blasts (%) (average) 63,1 64,8 0,9
    Peripheral Balsts % (average) 56 57,2 0,9
    PTTa seconds (average) 33,1 32,4 0,5


    The global burden of cancer has now reached 18.1 million new cases and 9.6 million deaths in 2018. In Africa, particularly in Ivory Coast, the incidence of AL is increasing and according to Globocan 2, the number of new cases is 162. Tumor syndrome and bone marrow failure were the components of the patient’s clinic and are the result of malignant and clonal proliferation. During the study, tumor syndrome was 45 % present. This result can be superimposed on that obtained by Lachachi: 43.5 % 14. However, it differs from that observed by Packo 15, which found 51.8 % of cases. Tumor syndrome is almost present during LA. It is the result of infiltration of the haematopoietic organs by leukaemia cells (blasts).

    The AL hemogram showed hyperleukocytosis with an average white blood cell count of 103,000 / mm3. Important hyperleukocytosis (> 100,000 / mm3) was observed in 35 % of patients. This result is different from those obtained by Lachachi and Jmili & al. 14, 16 who observed frequencies of 12 % and 14.5 % respectively. A late diagnosis, and therefore at an advanced stage of pathology could explain this difference. Indeed, in our socio-demographic context, patients come to see months after the first signs appear. And therefore, because of cell proliferation, hyperleukocytosis would occur.

    Observation of different peripheral blood smears had reported peripheral blastosis in 100 % of cases. This result is in perfect agreement with those obtained by Lachachi (93.9 %) as well as Jmili & al. (92 %) 14, 16. At the medullary level, blastosis was just as present with an average blast rate of 57 %. However, this result is different from that obtained by Lachachi, 14 who observed an average rate of spinal blasts of 65.74 %.

    Cytology has shown a predominance of acute myeloid leukaemia (80 %) and 20% of acute lymphoid leukaemia. These results are in agreement with those obtained by Lachachi 14 who observed 74.8 % of LAM and 25.2 % of LAL. Harioly et al. 17 and Nafil & al. 18 also observed a predominance of the myeloid lineage in their respective series. However, Packo 15 had observed a predominance of the lymphoid line with 51.8 % of cases.

    At haemostasis, a prolongation of the PTTa was observed in 50 % of cases and an extension of the QT in 40 % of cases. These results are different from those of Dixit & al. 19 which recorded extended PTTA and QT values in 6% and 49.3% of cases respectively 19. The study showed that 65 % of subjects had fibrinogen elevation and 95 % had D-Dimers’s elevation. These results are different from those observed by Dixit & al. 19 who obtained a normal value of fibrinogen in the entire study population; and an increase in D-Dimers in 29.9 %.

    Cancer cells can interact with clotting processes both directly and indirectly. The direct route could be the expression of TF on the surface of the tumor cell. The result would the formation of a procoagulant cancer cell, which would cause the direct activation of the X-factor. Many authors have shown that a high proportion of patients with acute leukaemia have a clotting abnormality at the time of diagnosis. This would contribute to both the thrombotic tendency and the bleeding.

    The risk of occurrence of Disseminated Intravascular Coagulation was present in 17.5 % of cases. This result is different from that obtained by Dixit & al. and Yanada & al who observed values ​​of 14.9 % and 29 % respectively 20. Within the lymphoid lineage, one subject in eight (12.5 %) presented a risk of DIC occurring. In contrast, 6 out of 32 subjects (18.75 %) in the myeloid lineage were at risk of DIC occurring. These results are different from those of Yanada & al. 20 who observed values of 28 % within the lymphoid lineage and 29 % in the myeloid lineage.

    By increasing some characteristics of the study population (such as age, sex, hemoglobin level, white blood cells, blastosis and PPTa) with the presence or not of the risk of DIC occuring, no statistically significant variation was been observed. The same constant was realized by Yanada & al. 20 for hemoglobin, white blood cells and platelets. However Dixit & al. 19 have shown a significant variation for the PPTa within the lymphoid lineage.


    The study of hypercoagulability on 40 samples of acute leukaemia demonstrated that there was a risk of disseminated intravascular coagulation in 17.5% of cases according to the criteria of ISTH. Thus, the risk of DIC occurring is indeed present during acute leukaemia. The parameters of haemostasis thus appear to be essential data in the additional assessment during the diagnosis of acute leukaemia.

    Nevertheless, understanding the set of pathophysiological mechanisms that support thrombosis formation during acute leukemias would require further exploration by the dosage of FT, factor VII, and some physiological clotting inhibitors such as antithrombin III, C protein and S protein.


    1.Hollard D. (1983) Leucémies aigues. , EMC (Paris-France). Sang 5, 13.
    2.Globocan. (2018) InfoCancer - ARCAGY - GINECO - Localisations - Cancers du sang - Hémopathies - Leucémie Aiguës (LA) - Formes de la maladie - Les leucémies lymphoblastiques.
    3.Zenhäusern R, Zwicky C, Solenthaler M, Fey M F, Tobler A. (2003) Leucémies aigues de l’adulte. In EMH Media. 684 92.
    4.Elice F, Rodeghiero F. (2012) Hematologic malignancies and thrombosis. Thrombosis Res. 129, 360-6.
    5.Del Principe MI, Del Principe D, Venditti A. (2017) Thrombosis in adult patients with acute leukemia. , Curr Opin Oncol 29(6), 448-54.
    6.Elalamy I. (2006) Coagulation intravasculaire disséminée. , Hématologie
    7.Boral B M, Williams D J, Boral L I. (2017) Disseminated Intravascular Coagulation. , Am J Clin Pathol 146(6), 670-80.
    8.Thachil J. (2016) Disseminated intravascular coagulation - new pathophysiological concepts and impact on management. Expert Rev Hematol. 2016/07/05. Août 9(8), 803-14.
    9.Rahman F, Kabir A L, Khan M R, Aziz A, Baqui M N et al. (2013) Disseminated intravascular coagulation in acute promyelocytic leukaemia and its impact on the induction failure: a single centre study. , Bangladesh Med Res Counc Bull. Août 39(2), 57-60.
    10.Stein E, McMahon B, Kwaan H, Altman J K, Frankfurt O et al. (2009) The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract Res Clin Haematol. 22(1), 153-63.
    11.Falanga A, Russo L, Montesinos P. (2018) . Acute Promyelocytic Leukemia. Acute Promyelocytic Leuk Clin Guide 55.
    12.Kwaan H C, Cull E H. (2014) The coagulopathy in acute promyelocytic leukaemia – What have we learned in the past twenty years. Acute Promyelocytic Leukemia. 27(1), 11-8.
    13.Toh C, Hoots W. (2007) SSC on Disseminated Intravascular Coagulation of the ISTH. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5‐year overview 1. , J Thromb Haemost 5(3), 604-6.
    14.Lachachi S. (2018) Profils épidémiologique et biologique des leucémies aiguës chez l’adulte au CHU Tlemcen.
    15.Packo S-C. (2019) Aspects actuels des leucémies Aigues à Bangui (République Centrafricaine): A propos de 27 cas. 7 août.
    16.Jmili N B, ABA Aziz, Nagara M, Mahjoub T, Ghannem H et al. (2005) Profil épidémiologique et cytologique des leucémies aiguës À propos de 193 cas colligés au centre Tunisien. Rev Fr Lab. 23, 28.
    17.Harioly Nirina MOM, Rakotoarivelo Z L, Ntoezara A, Rasolonjatovo A S, RakotoAlson A O et al. (2015) Épidémiologie et diagnostic des leucémies aiguës à l’hôpital Ravoahangy Andrianavalona Antananarivo Madagascar. , J Afr Cancer Afr J Cancer 7(4), 186-9.
    18.Nafil H, Tazi I, Faez S, Benchemsi N. (2012) Profil cytologique des leucémies aiguës à Casablanca. , J Afr Cancer Afr J Cancer 4(2), 79-83.
    19.Dixit A, Chatterjee T, Mishra P, Kannan M, Choudhry D R et al. (2007) Disseminated intravascular coagulation in acute leukemia at presentation and during induction therapy. , Clin Appl Thromb 13(3), 292-8.
    20.Yanada M, Matsushita T, Suzuki M, Kiyoi H, Yamamoto K et al. (2006) Disseminated intravascular coagulation in acute leukemia: clinical and laboratory features at presentation. , Eur J Haematol 77(4), 282-7.